Tremelimumab

Tremelimumab is an immunotherapy drug designed to help the immune system fight cancer. It works by blocking a protein called CTLA-4 on immune cells, which normally acts as a brake to prevent immune responses. By inhibiting CTLA-4, tremelimumab boosts the activity of immune cells, especially T-cells, enabling them to better recognize and attack cancer cells. This approach is used primarily in the treatment of certain cancers, such as melanoma and other solid tumors, aiming to improve the body’s natural ability to combat cancer more effectively.